Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA4 | P22748 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326763 | 0.79 | TSHR (0.46) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL916141 | 0.79 | MAOA (0.56) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL12932621 | 0.78 | EGFR (0.42) | AOC3CA1CA2CA4CA7 | |
| SCHEMBL12932619 | 0.77 | MAOA (0.47) | AOC3MAOAMAOBMTNR1AMTNR1B | |
| SCHEMBL1540520 | 0.76 | HTR2A (0.47) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL14565232 | 0.76 | MAOA (0.53) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL8857099 | 0.76 | MAOA (0.53) | MAOAMAOBCA1CA2CA4 | |
| Alcohol SCHEMBL914156 | 0.76 | MAOA (0.53) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL1496667 | 0.76 | MAOA (0.53) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL6272892 | 0.75 | AOC3 (0.46) | AOC3CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
| WO-2005080319-A1 | HYDRAZINO ALCOHOL DERIVATIVES USEFUL AS INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | VCAM1, VAPB, VAPA | AOC3 104/4885MAOA 1277/4885MAOB 1630/4885 |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | VAPB, VCAM1, VAPA | AOC3 111/4885MAOA 1327/4885MAOB 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.